Cardiol Therapeutics expands Phase III MAVERIC trial to up to 150 patients for CardiolRx in recurrent pericarditis

By Public Technologies
  • Cardiol Therapeutics expanded its Phase III MAVERIC trial of CardiolRx in recurrent pericarditis to up to 150 patients.
  • The original 110-patient enrollment target was reached ahead of the end-of-September timetable.
  • A blinded review showed fewer recurrences than expected, prompting the expansion to support a clearer efficacy readout.
  • Topline results have not been presented yet; the company now expects them in mid-2027, later than prior Q1 2027 guidance.
  • Management expects existing capital to fund completion, extending cash runway into Q1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609230600CANADANWCANADAPR_C2617) on September 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.